<DOC>
	<DOCNO>NCT01583322</DOCNO>
	<brief_summary>Patients extensive bulky disease often whose initial surgery delay 3 4 cycle neo-adjuvant chemotherapy . In case , , indeed , concern administer bevacizumab chemotherapy surround interval debulking surgery due long half life ( 14- 21 day ) monoclonal antibody interference anti angiogenic agent wound heal . Vargatef® ( Nintedanib ) might offer well alternative bevacizumab neo-adjuvant setting . Vargatef® ( Nintedanib ) much short half-life 7 19 hour . Preliminary experience cancer show trend increase incidence fistula bowel perforation . For detail please refer investigator drug brochure Vargatef® ( Nintedanib ) . This trial compare progression-free survival surgical complication 188 patient FIGO stage IIIC/IV treat first line either neo-adjuvant chemotherapy ( carboplatin &amp; paclitaxel ) interval debulking surgery treatment + Vargatef® ( Nintedanib ) .</brief_summary>
	<brief_title>Vargatef Addition First Line Chemotherapy With Interval Debulking Surgery Patients With Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>First diagnosis histological confirmed ( cytology alone exclude ) epithelial ovarian cancer , fallopian tube primary peritoneal cancer . Histology obtain laparoscopy ( laparotomy ) , FIGOStages IIIC IV , ECOG performance status &lt; 2 , Life expectancy least 6 month , Primary debulking surgery deny maximum surgical effort cytoreduction goal residual disease plan interval debulking surgery , Interval diagnosis enrolment ( informed consent ) ≤ 8 week , Adequate hepatic , renal bone marrow function : Platelets &gt; 100 000 /μL , Hemoglobin &gt; 9.0 g/dL , Absolute Neutrophil Count ( ANC ) &gt; 1500/μL , Prothrombin time and/or partial thromboplastin time &lt; 50 % deviation normal limit absence therapeutic anticoagulation , Proteinuria &lt; CTCAE grade 2 , Total bilirubin ≤ upper limit normal ( ULN ) , ALT and/or AST ≤ 2.5 x ULN , Glomerular filtration rate &gt; 40 mL/min , Females , age 18 year old , Patient give write informed consent , Histological diagnosis malignant tumour nonepithelial origin ( e.g . germ cell tumour , malignant mixed mullerian tumour , sex cordstromal tumour ) ovary , fallopian tube peritoneum borderline tumour ovary ( tumour low malignant potential ) , Nonhealing wound , ulcer ( intestinal tract , skin ) bone fracture , Clinical symptom sign gastrointestinal obstruction , History major thromboembolic event , define : Pulmonary embolism ( PE ) within 6 month prior enrolment , Recurrent pulmonary embolism ( history least 2 event ) , History least 2 unprovoked ( without transient reversible risk factor ) event proximal deep venous thrombosis , Prior thrombosis thromboembolic event presence inherit coagulopathy ( include deficiency antithrombin , deficiency protein C protein S , Factor V Leiden mutation , Prothrombin G20210A mutation ) , Patients perioperative thrombosis include proximal deep vein thrombosis ( DVT ) thrombosis visceral vessel associate pulmonary embolism may include trial stable therapeutic anticoagulation document , Known inherit acquire bleed disorder , Significant cardiovascular disease , include : Hypertension control medical therapy , Unstable angina within past 6 month , History myocardial infarction within past 6 month , Congestive heart failure &gt; NYHA II , Clinically relevant cardiac arrhythmia Peripheral vascular disease Fontaine stage ≥3 , Clinically relevant pericardial effusion ( e.g . pericardial effusion echocardiographic clinical sign haemodynamic impairment ) , History cerebral vascular accident , transient ischemic attack subarachnoid hemorrhage within past 6 month , Serious infection particular require systemic antibiotic ( antimicrobial , antifungal ) antiviral therapy , include HIVinfection , hepatitis B and/or C infection , Poorly control diabetes mellitus contraindication high dose corticosteroid therapy , Clinical symptom brain metastasis and/or diagnosis brain metastasis image , Preexisting sensory motor neuropathy CTCAE ≥ 2 , except due trauma , Gastrointestinal disorder abnormality would interfere absorption study drug , Other malignancy diagnose within past 5 year , except : nonmelanomatous skin cancer ( adequately treat ) , cervical carcinoma situ ( adequately treat ) , carcinoma situ breast ( adequately treat ) , prior synchronous endometrial cancer ( adequately treat ) , provide follow criterion meet : Disease stage FIGO ≤ IB , No superficial myometrial invasion , Not poorly differentiate ( less grade 3 , papillary serous clear cell histology ) , Prior systemic therapy ovarian cancer ( e.g . chemotherapy , monoclonal antibody therapy , oral target therapy , hormonal therapy ) , Prior radiotherapy abdomen prior radiotherapy extraabdominal target volume would bear risk increase toxicity chemotherapy , Hypersensitivity Vargatef® ( Nintedanib ) and/or excipients trial drug , Serious illness concomitant nononcological disease neurologic , psychiatric infectious disease , active ulcer ( gastrointestinal tract , skin ) laboratory abnormality may increase risk associate study participation study drug administration judgment investigator would make patient inappropriate entry study , Patients preserve reproductive capacity sexually active unwilling use medically acceptable method contraception ( e.g . implant , injectables , combine oral contraceptive , intrauterine device vasectomize partner ) trial least twelve month end active therapy , Pregnancy breast feeding , Psychological , familial , sociological geographical factor potentially hamper compliance study protocol followup schedule , Active alcohol drug abuse , Any contraindication therapy paclitaxel carboplatin , e.g . history severe hypersensitivity reaction paclitaxel platinumcontaining compound excipients , drug formulate Polyoxyl 35 Castor Oil ELP , Treatment investigational drug participation another clinical trial test drug within past four week start therapy concomitantly trial .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>ovarian cancer</keyword>
	<keyword>debulking surgery</keyword>
	<keyword>interval debulking</keyword>
	<keyword>vargatef</keyword>
	<keyword>nintedanib</keyword>
	<keyword>maintenance</keyword>
	<keyword>first line</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>carboplatin</keyword>
</DOC>